A convenient cancer vaccine therapy with in vivo transfer of interleukin 12 expression plasmid using gene gun technology after priming with irradiated carcinoma cells

Cancer Gene Therapy

Volumn 9, Issue 2, 2002, Pages 156-163

  Nishitani, Masa Aki ^a   Sakai, Tohru ^a   Ishii, Kazunari ^a   Zhang, Manxin ^a   Nakano, Yoko ^a   Nitta, Yoshio ^b   Miyazaki, Jun Ichi ^b   Kanayama, Hiro Omi ^a   Kagawa, Susumu ^a   Himeno, Kunisuke ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Autologous vaccine; Gene gun; Gene therapy; Interleukin 12; Murine renal cancer

Indexed keywords

CANCER VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; GENE PRODUCT; INTERLEUKIN 12;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER SURVIVAL; CANCER THERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG DELIVERY SYSTEM; GENE GUN; GENE INDUCTION; GENE THERAPY; GENETIC TRANSFECTION; IN VIVO STUDY; KIDNEY CANCER; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; SAFETY; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL LINE;

ANIMALS; BIOLISTICS; CANCER VACCINES; CARCINOMA, RENAL CELL; CELL DIVISION; COMBINED MODALITY THERAPY; DNA PRIMERS; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; IMMUNOENZYME TECHNIQUES; INJECTIONS, INTRALESIONAL; INTERLEUKIN-12; KIDNEY NEOPLASMS; LYMPH NODES; MALE; MICE; MICE, INBRED BALB C; PLASMIDS; POLYMERASE CHAIN REACTION; RNA, MESSENGER; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

ANIMALIA; MURINAE;

EID: 85047695965     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700419     Document Type: Article

References (35)

1. Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor)
2. Development of TH1 CD4+ T cells through IL - 12 produced by Listeria-induced macrophages
3. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes
4. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10
5. Antitumor and antimetastatic activity of interleukin 12 against murine tumors
6. Phase I trial of subcutaneous recombinant human interleukin- 12 in patients with advanced renal cell carcinoma
7. Cancer trial of interleukin-12 halted
8. Cytokine gene therapy of cancer using gene gun technology: Superior antitumor activity of interleukin- 12
9. Gene gun-mediated IL-12 gene therapy induces antitumor effects in the absence of toxicity: A direct comparison with systemic IL-12 protein therapy
10. Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors
11. Interleukin 12 gene therapy of MHC-negative murine melanoma metastases
12. Gene gun-mediated delivery of an interleukin-12 expression plasmid protects against infections with the intracellular protozoan parasites Leishmania major and Trypanosoma cruzi in mice
13. The JAM test. A simple assay for DNA fragmentation and cell death
14. The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor
15. DNA-based immunization by in vivo transfection of dendritic cells
16. Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization
17. DNA vaccination: Transfection and activation of dendritic cells as key events for immunity
18. MHC class I-restricted CTL responses to exogenous antigens
19. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen
20. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs
21. Immunogenicity of apoptotic cells in vivo: Role of antigen load, antigen-presenting cells, and cytokines
22. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation
23. Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12
24. The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes
25. Direct identification of major histocompatibility complex class I-bound tumor-associated peptide antigens of a renal carcinoma cell line by a novel mass spectrometric method
26. A hsp70-2 mutation recognized by CTL on a human renal cell carcinoma
27. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
28. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation
29. Selective loss of human leukocyte antigen class I allele expression in advanced renal cell carcinoma
30. HLA class I antigens expression in renal cell carcinoma: Histopathological and clinical correlation
31. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity
32. Effective eradication of established murine tumors with IL - 12 gene therapy using a polycistronic retroviral vector
33. Progress reports on immune gene therapy for stage IV renal cell cancer using lethally irradiated granulocyte-macrophage colony-stimulating factor - Transduced autologous renal cancer cells
34. Therapeutic vaccination against metastatic carcinoma by expression-modulated and immunomodified autologous tumor cells: A first clinical phase I/II trial
35. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma